On a mission to change the world for patients with serious cardiovascular disease through bold and innovative science


MyoKardia (NASDAQ: MYOK) is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.


Year Invested: 2012
Location: South San Francisco, Calif.
Visit: www.myokardia.com

Recent News

March 6, 2019
MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference

March 4, 2019
MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM

February 28, 2019
MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results

Read More News

Associated Team Members

Kevin Starr
Partner

Charles Homcy, M.D.
Partner

Eric Green, M.D., Ph.D.
Entrepreneur-in-Residence